Differences in MPS I and MPS II Disease Manifestations
Mucopolysaccharidosis (MPS) type I and II are two closely related lysosomal storage diseases associated with disrupted glycosaminoglycan catabolism. In MPS II, the first step of degradation of heparan sulfate (HS) and dermatan sulfate (DS) is blocked by a deficiency in the lysosomal enzyme iduronate...
Main Authors: | Christiane S. Hampe, Brianna D. Yund, Paul J. Orchard, Troy C. Lund, Jacob Wesley, R. Scott McIvor |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/15/7888 |
Similar Items
-
Clinical and Molecular Characterization of Patients with Mucopolysaccharidosis Type I in an Algerian Series
by: Abdellah Tebani, et al.
Published: (2016-05-01) -
Home treatment of type VI mucopolysaccharidosis (Maroteaux‐Lamy syndrome) an alternative at this time of COVID‐19 pandemic: A case in Peru
by: Jenny Lucy Cortez Miranda, et al.
Published: (2020-12-01) -
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients
by: Akhil Bhalla, et al.
Published: (2020-07-01) -
High-Throughput Liquid Chromatography–Tandem Mass Spectrometry Quantification of Glycosaminoglycans as Biomarkers of Mucopolysaccharidosis II
by: Junhua Wang, et al.
Published: (2020-07-01) -
A Possible Role for Arylsulfatase G in Dermatan Sulfate Metabolism
by: Aleksandra Poterala-Hejmo, et al.
Published: (2020-07-01)